| abstract |
The present invention relates to a GLP-1 compound conjugated to at least one polyethylene glycol molecule, which provides a bioactive peptide with an extended half-life and delayed clearance compared to an unPEGylated peptide. Or a derivative thereof. These PEGylated GLP-1 compounds and compositions are useful for diabetes, obesity, irritable bowel syndrome, and reducing blood glucose, suppressing stomach and / or intestinal motility, and stomach and / or intestines. Useful in treating other health conditions where it is beneficial to reduce content excretion or to reduce food intake. |